Company attributes
Other attributes
The company states that it is primarily interested in developing novel oral medicines for rare diseases to help patients enjoy regular life. They create synthetic compounds through the combination of cell biology and medicinal chemistry. The company looks to discover new drugs, clinical development, and regulatory affairs and also look to generate new compounds.
COVID-19
BioCryst Pharmaceuticals has taken part in taking action in response with the coronavirus (COVID-19) outbreak. They have provided their antiviral drug Galidesivir which acts against a wide range of pathogens, which includes the coronavirus. Their product is a nucleoside RNA polymerase inhibitor that disrupts viral replication processes found in Ebola, Zika, Marburg, and Yellow Fever. The development stage moves through animals first to test coronaviruses, flaviviruses, paramyxoviruses, and other rare viruses.
RNA polymerase lend a crucial role in viral replication processes, and inhibitors such as Galidesivir bind to the viral enzyme active site and becomes incorporated into the viral RNA strand. This leads to a premature chain termination.
